Efeito antinociceptivo do 3-(4-clorofenilselenil)-1-metil-1H-indol em camundongos

Abstract

Pain and inflammation are conditions that affect countless people every day around the world. With this, the search for new compounds for the treatment of pain and inflammation, which have fewer adverse effects and improve the patients' quality of life continues to be of great interest to the research groups. Several studies have shown the promising properties of the organic compounds of selenium and of the heterocyclic compounds containing the indole nucleus in antinociceptive and anti- inflammatory activities. Therefore, the objective of this work was to evaluate the antinociceptive and anti-inflammatory action of 3-(4-chlorophenylselenyl) -1-methyl- 1H-indole (CMI) in swiss mice. The antinociceptive activity of the compound was evaluated in the nociception tests induced by chemical agents (formalin and glutamate) and thermal (hot plate). The anti-inflammatory potential was evaluated in formalin-induced paw edema and in ear edema induced by croton oil. In addition, we investigated the involvement of the serotonergic, noradrenergic, dopaminergic, adrenergic and opioidergic systems in the antinociceptive action of CMI through the glutamate-induced nociception test. The open field test was performed to verify that the compound does not lead to locomotor changes in the animals. Intragastric (i.g.) administration of CMI (0.01-10 mg / kg) was able to reduce glutamate and formalin- induced nociception in both phases, and the dose of 0.1 mg / kg was able to increase the time on the hot plate test. In addition, CMI was able to reduce formalin-induced paw edema (0.01 mg/kg) and chromate oil-induced ear edema (0.1 mg/ kg). The pre- treatment of the mice with the SCH23390 (D1 receptor antagonist, 0.05mg/kg, intraperitoneally [i.p.]), WAY100635 (5-HT1A receptor antagonist, 0.7 mg/kg, i.p.), ondansetron (5-HT3 receptor antagonist, 0.5mg/kg, i.p.), ketanserin (5-HT2A/2C receptor antagonist, 0.3 mg/kg, i.p.), naloxone (non-selective antagonist 1 mg/kg, i.p.), caffeine (non-selective antagonist, 3 mg/kg, i.p.) and prazosin (α1 receptor antagonist, 0.15 mg/kg, i.p) blocked the nociceptive action of CMI (0.01 mg / kg). In this way, these results demonstrate the involvement of the dopaminergic, noradrenergic, serotonergic, adrenergic and opioidergic system in the antinociceptive activity of the CMI. The locomotor activities were not altered in the open field test after treatment with the IMC. From the obtained results, it can be suggested that the CMI has antinociceptive and anti-inflammatory action, thus being a promising molecule in the development of future therapeutic strategies for pain and inflammation.